Genprex

Our

Technologies


21st Century Gene Therapies

Our technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Our teams work closely with world-class researchers, institutions and industry collaborators to expand our pipeline of gene therapies and provide a wider range of novel treatment approaches for patients with cancer and diabetes.

Systemic Gene Therapy Platform for Cancer

Genprex’s oncology drug development program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which we believe is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient.

REQORSA™ Immunogene Therapy

Our lead product candidate, REQORSA™ immunogene therapy drug (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC), uses our unique, proprietary ONCOPREX® nanoparticle delivery system, a systemic gene therapy platform for cancer. The active ingredient in REQORSA is the TUSC2 gene, a tumor suppressor gene. In January 2020, the FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso® (osimertinib) in NSCLC patients with EFGR mutations whose tumors progressed after treatment with Tagrisso.

Diabetes Gene Therapy

GPX-002, a gene therapy for diabetes, is the most recent addition of our licensed technologies. GPX-002 was developed by researchers at the University of Pittsburgh. Diabetic mice studies have shown that GPX-002 restored normal blood glucose levels for an extended period of time, which could translate to decades in humans. This gene therapy could not only become a new treatment option for millions of diabetic patients who need insulin replacement therapy, but it holds the potential to provide long-term effectiveness, or may even be a cure, for diabetic patients.

Tagrisso® is a registered trademark of AstraZeneca.